CSIMarket
 
Cytek Biosciences Inc   (NASDAQ: CTKB)
Other Ticker:  
 
 
Price: $5.4600 $-0.03 -0.546%
Day's High: $5.6 Week Perf: -24.27 %
Day's Low: $ 5.37 30 Day Perf: -17.02 %
Volume (M): 706 52 Wk High: $ 9.33
Volume (M$): $ 3,853 52 Wk Avg: $6.27
Open: $5.56 52 Wk Low: $4.66



 Market Capitalization (Millions $) 725
 Shares Outstanding (Millions) 133
 Employees 254
 Revenues (TTM) (Millions $) 200
 Net Income (TTM) (Millions $) -10
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 4

Cytek Biosciences Inc
Cytek Biosciences Inc is a leading life science company specializing in the development and manufacture of innovative flow cytometry solutions.
They provide a range of products and services for research, clinical and industrial applications.
Founded in 2011, the company is headquartered in Fremont, California, with additional offices in South Korea and China.
Cytek Biosciences has developed a unique flow cytometer platform called Aurora, which is designed to enable high-resolution analysis of up to 50 parameters in a single cell.
This system is particularly well-suited for applications such as immune monitoring, cell therapy, drug discovery, and cancer research.
The Aurora flow cytometer is also capable of analyzing rare cell populations, including circulating tumor cells and stem cells.
In addition to their cutting-edge technology, Cytek Biosciences offers a range of services to support their customers, including assay development, data analysis, and technical support.
Their expert team of scientists and engineers collaborate with researchers and clinicians around the world to develop customized solutions that meet their specific needs.
Cytek Biosciences is committed to advancing scientific research through their innovative technology and collaborative approach.
With their state-of-the-art flow cytometry solutions, they are helping to drive breakthroughs in fields such as cancer immunotherapy, regenerative medicine, and infectious disease research.


   Company Address: 47215 Lakeview Blvd. Fremont 94538 CA
   Company Phone Number: 922-9835   Stock Exchange / Ticker: NASDAQ CTKB


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
A        3.81% 
AVTR        0.41% 
BRKR   -9.64%    
ILMN   -5.24%    
MTD        2.23% 
RVTY   -3.51%    
• View Complete Report
   



Product Service News

Cytek Biosciences Sets New Standards with First Subcellular Particle Detection Sorter and Clinically Approved Reagen...

Published Thu, Nov 7 2024 10:00 PM UTC

Cytek Biosciences Pioneers Subcellular Particle Detection and Achieves Regulatory MilestonesIn a remarkable advancement for the field of cell analysis and diagnostics, Cytek Biosciences has unveiled groundbreaking innovations that are set to redefine possibilities in scientific research and clinical applications. These developments not only highlight Cytek s commitment to a...

Management Announcement

Cytek Biosciences Obtains ISO 13485 Certification Amidst Challenging Financial Quarter

Published Wed, Aug 21 2024 9:00 PM UTC



Cytek Biosciences, a leading player in the healthcare sector, recently made...

Product Service News

Cytek Biosciences Pioneering Innovations in Cell Analysis and Global Expansion to Meet Demand

Published Tue, Jul 30 2024 9:00 PM UTC

In a remarkable convergence of technology and biological analysis, Cytek Biosciences is redefining the landscape of cellular diagnostics and analysis through a series of groundbreaking innovations. With the introduction of the SpectroPanel, an advanced automated panel design tool, alongside enhanced capabilities in small particle detection and the launch of a new facility in...

Cytek Biosciences Inc

CTKB's Revenue Soars in First Quarter of 2024, But Profitability Still Elusive

Cytek Biosciences Inc Reports Losses but Shows Revenue Growth Amidst Declining Industry
For the fiscal interval closing on March 31, 2024, Cytek Biosciences Inc, a leading provider of innovative cell analysis solutions, reported a loss of $-0.05 per share compared to a loss of $-0.05 per share in the previous year. Additionally, the company's income per share fell from $0.04 to $0.05 per share from the preceding quarter. Despite these setbacks, Cytek Biosciences' revenue grew a respectable 18.672% to $44.01 million from $37.09 million in the corresponding quarter a year before. However, sequentially, the revenue fell by -25.399% from $59.00 million.
The behavior of Cytek Biosciences Inc is surprisingly positive in contrast to the rest of the Laboratory Analytical Instruments sector, which has experienced a decline of -4.06% in top-line. In the fiscal interval ending March 31, 2024, Cytek Biosciences Inc reported a net shortfall of $-6.169 million, an improvement from a deficit of $-6.807 million in the corresponding quarter a year ago.

Cytek Biosciences Inc

Cytek Biosciences Inc. Surges in Revenue, Defying Market Trends

CTKB, the leading cell analysis solutions company, has reported strong financial results for the fourth quarter and fiscal year 2023. The company showcased impressive growth, with income per share rising by 101.19% year on year to $0.04 per share and revenue increasing by 22.058% to $59.00 million.
This growth is particularly noteworthy considering the downward trend in the Laboratory Analytical Instruments sector. CTKB has defied industry peers, who experienced a decline in top-line revenue during the same period. Additionally, when compared sequentially, CTKB demonstrated positive progress, with income per share improving from $-0.05 per share and revenue increasing by 25.054% from $47.18 million.







Cytek Biosciences Inc's Segments

  Cytek Biosciences Inc Outlook

On April 29 2024 the Cytek Biosciences Inc provided following guidance

Cytek Biosciences, a prominent company in the field of cell analysis solutions, has declared that it will disclose its financial results for the first quarter of 2024 on May 8, 2024, after the market closes. This announcement comes as the company aims to provide transparency and keep its investors informed about its performance.

The management of Cytek Biosciences will host a webcast conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day to discuss the financial results, business updates, and future prospects of the company. This conference call offers an opportunity for stakeholders to gain insights into the company's progress and strategies moving forward.

Investor...





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com